Nanocarriers and the delivered drug: effect interference due to intravenous administration.
Eur J Pharm Sci
; 63: 96-102, 2014 Oct 15.
Article
en En
| MEDLINE
| ID: mdl-24964293
ABSTRACT
Intravenously administered nanocarriers are widely studied to improve the delivery of various therapeutic agents. However, recent in vivo studies have demonstrated that intravenously administered nanocarriers that do not contain any drug may affect cardiovascular function. Here we provide an example where the drug and the nanocarrier both affect the same cardiovascular parameters following intravenous administration. The peptide ghrelin antagonist (GhA) increases arterial pressure, while thermally hydrocarbonized porous silicon nanoparticles (THCPSi) transiently decrease it, as assessed with radiotelemetry in conscious rats. As a result, intravenous administration of GhA-loaded THCPSi nanoparticles partially antagonized GhA activity arterial pressure was not increased. When the cardiovascular effects of GhA were blocked with atenolol pretreatment, GhA-loaded nanoparticles reduced arterial pressure to similar extent as drug-free nanoparticles. These data indicate that the biological activity of a drug delivered within a nanocarrier may be obscured by the biological responses induced by the nanocarrier itself.
Palabras clave
Arterial pressure; Atenolol (PubChem CID: 2249); Chloramine T (PubChem CID: 3641960); Drug delivery; Ethanol (PubChem CID: 702); HEPES (PubChem CID: 23831); Hydrofluoric acid (PubChem CID: 14917); Intravenous; Lipopolysacharide (PubChem CID: 11970143); Mesoporous silicon (calcium silicate) (PubChem CID: 26370); Nanoparticles; Sodium chloride (PubChem CID: 5234); Tween 20 (PubChem CID: 443314); [D-Lys-3]-GHRP-6 (PubChem CID: 5311279)
Texto completo:
1
Base de datos:
MEDLINE
Asunto principal:
Péptidos
/
Portadores de Fármacos
/
Sistema Cardiovascular
/
Artefactos
/
Nanopartículas
Idioma:
En
Revista:
Eur J Pharm Sci
Asunto de la revista:
FARMACIA
/
FARMACOLOGIA
/
QUIMICA
Año:
2014
Tipo del documento:
Article